Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Scott Hubosky

Urology Philadelphia, PA Medical Doctor

NPI 1669451605 CMS profile 211061

833 Chestnut St, Suite 703, Philadelphia, PA 19107

Open in the dashboard

General payments

$8,779

56 records reported · program years 2019–2025

Research payments

$352

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Scott Hubosky of Philadelphia, PA is reported in the CMS Open Payments database as having received $8,779 across 56 general payments and $352 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $216 4
2024 General $826 10
2023 General $2,228 14
2022 General $1,651 8
2021 General $2,519 7
2020 General $513 2
2020 Research $352 1
2019 General $827 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Hubosky
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Scott Hubosky were reported at $216. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Scott Hubosky Urology median Middle half National median
2019 $827 $480 $147–$1,201 $163
2020 $513 $246 $87–$645 $114
2021 $2,519 $358 $111–$1,000 $132
2022 $1,651 $476 $143–$1,263 $149
2023 $2,228 $560 $168–$1,461 $160
2024 $826 $563 $170–$1,464 $164
2025 $216 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $7,611 30 payments
  2. C. R. Bard, Inc. & Subsidiaries $465 5 payments
  3. Calyxo, Inc. $155 4 payments
  4. Myriad Genetic Laboratories, Inc. $137 3 payments
  5. Ambu Inc. $119 1 payment
  6. Janssen Biotech, Inc. $65 3 payments
  7. Urogen Pharma, Inc. $60 2 payments
  8. Corcept Therapeutics $48 2 payments
  9. Smith+Nephew, Inc. $32 1 payment
  10. Coloplast Corp $30 2 payments
  11. Other $58 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $6,165 9 payments
  2. Food and Beverage $2,614 47 payments
Products named General payments · program years 2019–2025
  1. GENERAL KIDNEY STONE DISEASE $2,125 2 payments
  2. General - Kidney Stone Disease General - Kidney Stone Disease_URO $1,427 4 payments
  3. General - Kidney Stone Disease Kidney Stone Disease $500 1 payment
  4. LITHOVUE Scope $356 6 payments
  5. LithoVue LithoVue_URO $354 5 payments
  6. LITHOVUE Pain Management $142 1 payment
  7. PROLARIS $137 3 payments
  8. SpaceOAR VUE System - 10mL $102 1 payment
  9. General - Kidney Stone Disease General Kidney Stone Disease $99 1 payment
  10. CVAC ASPIRATION SYSTEM $94 1 payment
  11. Other $430 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Urogen Pharma, Inc. $352 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

747

Median for Urology: 1,053

Drug cost

$15,581

Median for Urology: $101,464

Branded share of claims

13.9%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tamsulosin Hcl Generic 350 $5,881
Potassium Citrate Er Potassium Citrate Brand 35 $4,426
Finasteride Generic 116 $2,127
Dutasteride Generic 26 $729
Penicillin V Potassium Generic 62 $522
Alfuzosin Hcl Er Alfuzosin Hcl Brand 20 $464
Allopurinol Generic 16 $343
Chlorthalidone Generic 14 $297
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 35 $262
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 14 $188

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$128,118

Medicare's payments for the services billed

Medicare patients

408

Average age 73

Services billed

1,298

153 women, 255 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Ischemic heart disease 39%
Chronic kidney disease 38%
Diabetes 35%
Cancer 25%
Atrial fibrillation 23%
Depression 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JELMYTO
  • UROGEN PHARMA, INC. $60
$60 — —
Korlym
  • Corcept Therapeutics $48
$48 — —
ERLEADA
  • Janssen Biotech, Inc. $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

57 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record